[HTML][HTML] An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in …
Background Mutations in SOD1 cause 13% of familial amyotrophic lateral sclerosis. In the
SOD1 Gly93Ala rat model of amyotrophic lateral sclerosis, the antisense oligonucleotide …
SOD1 Gly93Ala rat model of amyotrophic lateral sclerosis, the antisense oligonucleotide …
[HTML][HTML] Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models
WK Decker, RF da Silva, MH Sanabria… - Frontiers in …, 2017 - frontiersin.org
At the turn of the last century, the emerging field of medical oncology chose a cytotoxic
approach to cancer therapy over an immune-centered approach at a time when evidence in …
approach to cancer therapy over an immune-centered approach at a time when evidence in …
TGF-β signaling networks in the tumor microenvironment
Transforming growth factor-β (TGF-β) signaling shows important roles in both physiology
and pathology, especially in the progression of inflammatory diseases including cancer …
and pathology, especially in the progression of inflammatory diseases including cancer …
[HTML][HTML] The rational development of CD133-targeting immunotherapies for glioblastoma
CD133 marks self-renewing cancer stem cells (CSCs) in a variety of solid tumors, and
CD133+ tumor-initiating cells are known markers of chemo-and radio-resistance in multiple …
CD133+ tumor-initiating cells are known markers of chemo-and radio-resistance in multiple …
[HTML][HTML] A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials
E Cruz Da Silva, MC Mercier, N Etienne-Selloum… - Cancers, 2021 - mdpi.com
Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
O Van Tellingen, B Yetkin-Arik, MC De Gooijer… - Drug Resistance …, 2015 - Elsevier
Gliomas are the most common primary brain tumors. Particularly in adult patients, the vast
majority of gliomas belongs to the heterogeneous group of diffuse gliomas, ie. glial tumors …
majority of gliomas belongs to the heterogeneous group of diffuse gliomas, ie. glial tumors …
TGF-beta in CAF-mediated tumor growth and metastasis
TGF-beta signaling is one of the major pathways controlling cell and tissue behavior not only
in homeostasis but also in disease. During tumorigenesis TGF-beta orchestrated processes …
in homeostasis but also in disease. During tumorigenesis TGF-beta orchestrated processes …
Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma
RK Oberoi, KE Parrish, TT Sio, RK Mittapalli… - Neuro …, 2015 - academic.oup.com
Glioblastoma (GBM) is a lethal and aggressive brain tumor that is resistant to conventional
radiation and cytotoxic chemotherapies. Molecularly targeted agents hold great promise in …
radiation and cytotoxic chemotherapies. Molecularly targeted agents hold great promise in …
TGF-β/TGF-β receptor system and its role in physiological and pathological conditions
JF Santibañez, M Quintanilla, C Bernabeu - Clinical science, 2011 - portlandpress.com
The TGF-β (transforming growth factor-β) system signals via protein kinase receptors and
Smad mediators to regulate a plethora of biological processes, including morphogenesis …
Smad mediators to regulate a plethora of biological processes, including morphogenesis …
[HTML][HTML] SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis
Distant metastasis is the main cause of breast cancer-related death; however, effective
therapeutic strategies targeting metastasis are still scarce. This is largely attributable to the …
therapeutic strategies targeting metastasis are still scarce. This is largely attributable to the …